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Introduction
A recent trend in global health has been
a growing emphasis on measuring the
value of development assistance for health
(DAH) and the use of models to estimate
the health impact of specific health
interventions. Many international donor
agencies and global health partnerships
now publish quantifiable results that are
said to be attributable to their funding and
initiatives (see Box 1).
While this may seem sensible at face
value, critical examination from at least
two angles is needed. First, from a
methodological perspective, there are
questions about the validity and accuracy
of published measures of health impact.
Second, from a policy perspective, there
are concerns about how the attribution of
health impact to individual programmes or
actors might affect the overall governance
and management of health systems.
In this Policy Forum article, we critically
assess several methodological and policy
issues related to the estimation of the
number of ‘‘lives saved’’ by The Global
Fund to Fight AIDS, Tuberculosis and
Malaria (The Global Fund hereafter) as a
case study. The Global Fund was estab-
lished in 2002 to help finance the scale-up
of HIV, tuberculosis (TB), and malaria
programmes and was chosen as a case
study because it is a major provider of DAH
and was established explicitly to develop a
performance-based funding model.
This paper begins by summarising the
published figures of The Global Fund’s
estimation of ‘‘lives saved.’’ We then
describe The Global Fund’s approach
and methodology for estimating ‘‘lives
saved.’’ This is followed by a discussion
of three issues: (1) the degree of uncertain-
ty associated with the estimated figures
and the potential for bias; (2) the decision
to attribute results to ‘‘Global Fund–
supported programmes’’ (as distinct from
The Global Fund alone) and the double
counting of ‘‘lives saved’’ by other agen-
cies; and (3) the implications of measuring
the health impact of only a selected
number of interventions. This is followed
by a discussion that includes certain
recommendations.
The Global Fund’s Estimate of
‘‘Lives Saved’’
According to The Global Fund’s 2012
Results Report, 8.7 million lives were
saved between 2002 and the middle of
2012 through support for the provision of
antiretroviral therapy (ART) to 3.6 million
people; directly observed tuberculosis
treatment, short course (DOTS) for 17.8
million new cases of TB; and the distribu-
tion of 270 million insecticide-treated
mosquito nets (ITNs) [7].
The report does not provide a break-
down of the number of ‘‘lives saved’’ by
each intervention, nor for each year since
2002. An earlier estimation using a similar
methodology indicated that at the end
of 2007, DOTS was responsible for
67% of all lives saved by Global Fund–
supported programmes, while ART and
ITNs contributed 28% and 5%, respec-
tively [8]. However, these proportions will
have changed due to the extensive scale-
up of ITNs since 2008 leading to
greater reductions in mortality due to
malaria [9].
Global Fund’s Modelling
Approach and Methodology
The Global Fund’s estimate of ‘‘lives
saved’’ is based on service delivery results
consisting of: number of patients alive on
ART; number of TB cases placed on
DOTS treatment; and number of ITNs
distributed to households. The reliability
of these results is assumed, with The
Global Fund claiming to have established
various practices to ensure good reporting
by grantees [10] and to have excluded
results from countries ‘‘with serious data-
quality issues.’’ However, because of The
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Global Fund’s performance-based funding
model, grant recipients clearly have strong
incentives to over-report performance.
The number of ‘‘lives saved’’ is calcu-
lated by comparing the estimated mortal-
ity among beneficiaries of ART, DOTS,
and ITNs with anticipated mortality rates
in a counterfactual ‘‘no-treatment/
intervention’’ scenario. The difference in
the number of deaths between these
two scenarios is taken as an estimate of
the number of lives saved by these
interventions. Numbers are calculated
separately for each intervention and year,
and then aggregated into a single figure for
publication.
Service delivery results are transformed
into estimates of ‘‘lives saved’’ by a
modelling exercise that uses additional
data on: (1) the quality and effectiveness
of ART, DOTS, and ITNs; (2) baseline
mortality rates and their causes; (3) the
clinical and demographic profile of pa-
tients; and (4) treatment compliance and
ITN usage rates. Details of the model’s
methodology for each intervention are
summarised in Box 2.
Issue 1: Uncertainty and Bias
The methods described in Box 2
depend on a number of extrapolations,
assumptions, and generalisations. The
number of ‘‘lives saved’’ produced by the
model is thus inevitably uncertain.
In the case of ART, while survival rates
are adjusted to account for regional
variations in CD4 count, age, sex, and
duration of treatment [11,12], the model
takes no account of intra-regional varia-
tions and assumes a universal standard of
treatment quality and adherence, as well
as a uniform set of social and economic
determinants of health [24,25], which is
far from reality. Reliable measures of the
number of patients lost to follow-up after
treatment initiation are especially impor-
tant; but in 2008, only 17 out of 47
countries in sub-Saharan Africa reported
data on treatment retention at 24 months
[26].
In the case of DOTS, the degree of
uncertainty associated with a single as-
sumed mortality effect is illustrated by a
meta-analysis of TB case fatality ratios
(CFRs) amongst DOTS-treated HIV-
negative patients in 19 research studies,
which resulted in a pooled CFR of 3.5%
but with a 95% confidence interval
ranging from 2.5% to 7.2% [27]. Likewise,
the assumed 17% child mortality reduc-
tion impact of ITNs is held to be true for
countries and settings with different base-
line mortality rates and patterns of
disease. A further reason for uncertainty
is the assumed under-five child mortality
rates used in the model; in many countries,
vital registration data are incomplete and
unreliable, and mortality rates have to be
derived from population-based surveys
that are often conducted once every 5
years [28].
While uncertainty is to be expected
from a modelling exercise, the degree of
uncertainty is not reported: although
uncertainty ranges have been calculated,
neither the statistical methods used nor
the results are publicly available. How-
ever, a paper on the estimated ‘‘lives
saved’’ by Global Fund–supported pro-
grammes between 2003 and 2007 did
publish 95% uncertainty ranges as
follows: 619,000 to 774,000 lives for
ART; 1.09 to 2.17 million lives for
DOTS; and 27,000 to 232,000 lives for
ITNs [8].
A more critical question is whether
there is any bias towards either under- or
overestimating the number of ‘‘lives
saved.’’ In the case of ART, assumptions
about treatment effectiveness are almost
certainly optimistic, having been largely
derived from small-scale research studies,
clinical trials, and demographic surveil-
lance sites [24,29,30] where the quality of
Summary Points
N A recent trend in global health has been a growing emphasis on assessing the
effectiveness and impact of specific health interventions.
N For example, it has been estimated that 8.7 million lives were saved between
2002 and mid-2012 by ‘‘Global Fund–supported programmes’’ (as distinct from
The Global Fund alone) through antiretroviral therapy (ART); directly observed
tuberculosis treatment, short course (DOTS); and distribution of insecticide-
treated mosquito nets (ITNs).
N This paper assesses the methods used by The Global Fund to quantify ‘‘lives
saved,’’ highlights the uncertainty associated with the figures calculated, and
suggests that the methods are likely to overestimate the number of ‘‘lives
saved.’’
N The paper also discusses how the attribution of ‘‘lives saved’’ to specific
programmes or actors might negatively affect the overall governance and
management of health systems, and how a narrow focus on just ART, DOTS,
and ITNs could neglect other interventions and reinforce vertical programmes.
N Furthermore, the attribution of ‘‘lives saved’’ to Global Fund–supported
programmes is potentially misleading, because such programmes include an
unstated degree of financial support from recipient governments and other
donors.
Box 1. Examples of the Quantification and Attribution of Results
and Health Impact to DAH and Specific Health Interventions
The GAVI (Global Alliance for Vaccines and Immunisation) Alliance claims to have
prevented more than 5.5 million child deaths since 2000, through immunizations
against vaccine-preventable diseases [1].
The International Development Association reports having immunized 343
million children and given ART to 1.5 million people with HIV [2].
The US President’s Emergency Plan for AIDS Relief (PEPFAR) asserts that ‘‘The US
directly supported life-saving antiretroviral treatment for nearly 5.1 million men,
women and children worldwide’’ as of September 2012 [3].
According to the STOP TB Partnership, 20 million lives have been saved through
TB care and control between 1995 and 2011 [4].
According to the Roll Back Malaria partnership, ITNs and intermittent preventive
treatment for pregnant women is estimated to have prevented 842,800
(uncertainty range: 562,800–1,364,645) child deaths due to malaria across 43
malaria-endemic countries in Africa between 2001 to 2010 [5].
According to WHO, UNICEF, and UNAIDS, the introduction of ART has averted 2.5
million deaths in low- and middle-income countries between 1995 and end-2010
[6].
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care and treatment retention rates are
better than in real-world settings.
One meta-analysis of 33 patient co-
horts observed in 22 sub-Saharan African
countries between 2000 and 2007 [26]
found ART retention rates to be as low as
75% at 12 months and 67% at 24
months—lower than the rates assumed in
the Spectrum HIV/AIDS epidemic model
for Africa. It should also be noted that the
rapid increase in size of many ART
programmes in recent years has been
accompanied by reductions in quality
and treatment retention [31–34]. In addi-
tion, in the few countries that have
measured adult mortality trends at a
population level during the roll-out of
ART (Thailand, South Africa, Botswana,
and Malawi), slower and smaller mortality
reductions were found than predicted by
the Spectrum model [35–39].
The assumed mortality impact of
DOTS is also likely to be overestimated,
primarily because the assumed mortality
rate of untreated pulmonary TB (used in
the counterfactual ‘‘no-treatment’’ scenar-
io) is based on a meta-analysis of studies
from the pre-chemotherapy era of hospi-
talised patients in the 1930s to 1960s from
western Europe and the US. Such
patients were mostly detected through
passive case finding, and would have
consisted of cases of more advanced and
severe TB when compared to current
cohorts of TB patients who are diagnosed
through more active case finding (using
improved microscopy and culture), with a
higher proportion of less severe cases.
Furthermore, untreated TB mortality
rates in poor countries from 2000 on-
wards might be lower than the untreated
TB mortality rates of western Europe and
the US from 1930 to 1960 due to
improvements in living standards and
public health.
A further issue about the estimation of
‘‘lives saved’’ by DOTS concerns the use
of a ‘‘no-treatment’’ counterfactual. In
contrast to ART and ITNs, the scale-up
of which corresponded with the establish-
ment of The Global Fund, treatment for
TB—including DOTS—was already well
established before 2002. Arguably, a more
appropriate estimate of ‘‘lives saved’’ by
Global Fund–supported programmes
would be derived by using a counterfac-
tual based on the coverage and effective-
ness of TB treatment in 2002, or on
estimated TB mortality rates from 1995,
which is the counterfactual used by the
WHO Stop TB programme to evaluate
the impact of the global DOTS/Stop TB
strategy [16]. Using the latter counterfac-
tual would result in a 3- to 4-fold reduction
in ‘‘lives saved’’ from TB from the current
estimate, reducing the number by several
million.
For ITNs, two possible reasons for over-
estimation in ‘‘lives saved’’ are: the opti-
Box 2. Details of the ‘‘Lives Saved’’ Model for Each Intervention
ART
An epidemiological modelling package (Spectrum) employs demographic and
HIV prevalence data and numbers of people on ART to predict trends in HIV-
related mortality, incidence and prevalence for each country, with and without
ART [6,11,12,13]. Spectrum assumes that ART is only provided to people in need
of such treatment, and takes into account the effects of ART on reducing HIV
transmission.
Survival rates on ART are derived from cohort studies of people on treatment
contained within established databases, including the International Epidemio-
logic Database to Evaluate AIDS (http://www.iedea.org/). Where previously,
Spectrum assumed a standard survival rate of 86% at 12 months after initiation of
treatment and 90% for each subsequent year, it now uses region-specific survival
rates for adults, which take into account regional estimates of patient profiles in
terms of CD4 count, age, and sex at initiation of treatment, and duration of
treatment [14]. Under the no-treatment scenario, Spectrum assumes a survival
rate of 50% at 12 months and 0% at 24 months, with some region-specific
adjustments made for age and sex. For children, who make up around 8% of
people living with HIV globally [6], Spectrum uses a standard on-treatment
survival rate of 85% for the first year and 93% for each subsequent year [13].
DOTS
The model is based on the assumption that every DOTS treatment saves 0.33 lives
compared to a no-treatment scenario, as also assumed by WHO’s Stop TB
program [4]. This assumed effectiveness is applied to all TB patients and was
derived from analyses of various studies and treatment outcome data reported by
national TB programmes from different settings [15,16,17,18,19], thus
incorporating variations in HIV and sputum smear status, the proportion of
patients with extrapulmonary disease, and treatment completion rates, all of
which influence mortality rates.
Up until 2012, most TB programmes only reported the number of newly treated
smear-positive TB patients to the Global Fund. In order to incorporate treatments
of smear-negative and extrapulmonary TB into the model, it is assumed that every
smear-positive TB case is accompanied by 0.92 of a case of non-smear–positive
TB, a figure derived from smear-positivity ratios that Global Fund–supported
programmes routinely report to the WHO [20].
The model does not include any estimation of the dynamic effects of DOTS in
reducing TB transmission and thereby reducing mortality through prevention.
ITNs
The ‘‘lives saved’’ by ITNs are estimated for countries with stable endemic
falciparum malaria (i.e., countries in sub-Saharan Africa and Papua New Guinea)
[21]. The assumed mortality impact of ITNs is only applied to children aged under
5 years of age, because of a lack of research-based estimates of the impact on
mortality in older age groups. Similarly, any ‘‘lives saved’’ by ITNs in other
countries are not included because of a lack of evidence of their mortality effect
in non-stable endemic areas.
The model assumes that ITNs distributed up to 2008 had an effective lifespan of
1.5 years, but from 2009 onwards, when most ITNs were long-lasting, a lifespan of
3 years was assumed. Each ITN distributed to a household is assumed to result in
0.73 children under 5 years of age sleeping under that ITN during its effective
lifespan [22]. The assumed impact on mortality is based on a meta-analysis of five
community randomized controlled trials of ITNs conducted in stable malaria
settings within four African countries, which estimated an all-cause mortality
reduction among children under the age of 5 years of 17% compared to control
areas where ITNs were not used at all [23]. The number of ‘‘lives saved’’ is derived
by applying the 17% mortality reduction to the estimated child population
covered by ITNs and to each country’s average all-cause under-five mortality rate
as estimated for 2009.
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mistic assumption about the degree to
which the number of ITNs distributed to
households is translated into actual usage;
and the recent scale-up of artemisinin-based
combination therapies (ACT) for malaria,
which is likely to decrease the relative
contribution of ITNs in reducing mortality
[40].
Finally, because the model calculates
‘‘lives saved’’ separately for each of the
three interventions and then adds these
figures together, the total number of ‘‘lives
saved’’ may be higher than the actual
number of people concerned. For example,
an individual co-infected with AIDS and TB
who receives ART and DOTS will be
counted as though two lives had been saved.
In practice, however, this double counting
may be minimal because The Global Fund
mainly supports ART provision in southern
and East Africa, while its support for DOTS
is concentrated in Asian countries [7].
On the other hand, some aspects of the
model may underestimate ‘‘lives saved.’’
One is the nonestimation of the effects of
ITNs on mortality in children over the age
of 5 years and in adults. There is some
evidence of reductions in malaria-attribut-
ed deaths in older age groups associated
with scaled-up ITN distribution [40,41,42],
and a recent analysis [43] claimed a greater
number of deaths due to malaria in
individuals over the age of 5 years than
previously thought, although adult malaria
mortality estimates continue to be disputed
[44]. A second aspect is the nonestimation
of the effects of ITNs in countries with
nonstable endemic malaria. The number of
malaria-related deaths in nonstable endem-
ic countries outside Africa in 2010 was
recently estimated to total about 104,000
[43], but given the relatively low level of
Global Fund support for ITNs in countries
outside Africa, the extent of underestima-
tion is likely to be small. Finally, a recent
analysis of household surveys across 22
African countries suggests that the effec-
tiveness of ITNs may be slightly greater
than that assumed in the model, despite
current ITN coverage rates being less than
those in the trials on which The Global
Fund based its model assumptions [41].
Table 1 summarises the likely causes for
both under- and overestimation, assuming
the reliability of the data submitted by grant
recipients, and suggests an overall overes-
timation of the number of ‘‘lives saved.’’
Issue 2: Attribution and Double
Counting
A curious feature of the Global Fund’s
approach to impact assessment is that it
estimates ‘‘lives saved’’ by Global Fund–
supported programmes and not by The
Global Fund alone [8]. In other words,
these are ‘‘lives saved’’ by programmes
that also receive financial support from
other donors and recipient governments,
as well as through out-of-pocket payments.
The procedure for attributing results to
Global Fund–supported programmes is
not entirely clear. According to The
Global Fund, patients alive on ART are
only counted if three criteria are met: The
Global Fund supports an essential element
of a country’s ART programme (e.g., drug
provision or laboratory testing) on a
national scale; and its HIV grants are
deemed to be performing adequately
(rated A or B1); and The Global Fund
has disbursed at least $50 million to the
country’s HIV programmes in the past 3
years or its total HIV disbursement
constituted at least 33% of total reported
domestic public expenditure on HIV
[22,45]. A similar set of criteria is used
to allocate ITN and DOTS results to
Global Fund–supported programmes, al-
though this is not published anywhere.
The scale of the difference between
‘‘lives saved’’ by Global Fund–supported
programmes and that of The Global Fund
alone can be gauged by comparing the
share of global service delivery results for
ART, DOTS, and ITNs attributed to
Global Fund–supported programmes
against The Global Fund’s share in global
financing for HIV/AIDS, TB, and malar-
ia, as shown in Table 2.
Thus, while about 45% of global ART
results have been attributed to Global
Fund–supported programmes, the contri-
bution of The Global Fund to total AIDS
programme financing in low- and middle-
income countries was only about 10%
[46]. Similarly, while about 68% of global
DOTS results and 62% of ITN results
were attributed to Global Fund–supported
programmes in 2010, The Global Fund’s
financial contribution to TB and malaria
programmes were 11% and 45%, respec-
tively [20,47].
The financial contribution of Global
Fund grants to total health expenditure
(THE) in low- and middle-income coun-
tries is also relevant because HIV/AIDS,
TB, and malaria programmes are signifi-
cantly reliant on various aspects of the
broader health system that are not funded
through disease-specific budgets. In 2009,
for example, Global Fund disbursements
made up only 0.37% of THE across 104
low- and middle-income countries that
The Global Fund funded that year [48].
The allocation of results to Global
Fund–supported programmes and the
subsequent estimation of ‘‘lives saved’’
from these results may easily be
misunderstood to reflect the impact of
The Global Fund alone. Furthermore, a
percentage of those results attributed to
Global Fund–supported programmes is
also claimed by other donor-supported
programmes. For example, at the end of
2010, PEPFAR reported having supported
3.2 million patients, while The Global
Fund reported having supported 3 million
patients; but the total number of patients
supported by PEPFAR and The Global
Fund combined was 4.7 million, meaning
that 1.5 million patients were claimed to
have been supported by both PEPFAR
and The Global Fund [49].
Issue 3: Selectivity
The headline figure of 8.7 million ‘‘lives
saved’’ is based on the estimated impact of
only three interventions. It excludes Glob-
al Fund support for other interventions,
including the prevention of vertical HIV
transmission; treatment of MDR-TB; HIV
testing and counselling; treatment of acute
malaria and non-HIV sexually transmitted
infections; promotion of condom use;
indoor residual spraying; and male cir-
cumcision. This selectivity is justified by
The Global Fund on the grounds that: (i)
there are relatively robust measures of the
effectiveness of ART, DOTS, and ITNs
on mortality; (ii) ART, DOTS, and ITNs
constitute a large part of The Global
Fund’s overall spending; and (iii) data
collection on ART, DOTS, and ITNs is
relatively good [8].
Nevertheless, this selective focus may
have adverse consequences. It may lead to
an overemphasis on ART, DOTS, and
ITNs at the expense of other services and
interventions. The fact that The Global
Fund’s 2012–2016 strategy includes nu-
merical targets for delivery of ART, ITNs,
and DOTS, but no such targets for other
‘‘essential’’ HIV, TB, and malaria services
[9], may be indicative of this.
In theory, The Global Fund could
estimate lives saved due to other interven-
tions that have an evidence base of
measured mortality reduction. However,
data-related deficiencies would result in
even greater degrees of uncertainty, and
there would be major methodological
challenges involved in having to disentan-
gle the separate and unique effects of
different interventions on the same popu-
lation to avoid the double counting
involved in ‘‘lives saved’’ calculations.
Regardless of the number of interven-
tions modelled, there are fundamental
questions about measuring and attributing
‘‘lives saved’’ to a selection of discrete
PLOS Medicine | www.plosmedicine.org 4 October 2013 | Volume 10 | Issue 10 | e1001522
interventions. The emotive metric of ‘‘lives
saved’’ could undermine investment in
interventions that are important but which
are not easily translated into a measure of
saved lives. These include interventions
whose impact may involve a prolonged
time lag or those which operate through
more complex and multi-staged pathways.
Examples include many health systems–
strengthening investments and interventions
aimed at improving the wider determinants
of health. It could also undermine invest-
ment in interventions that have a greater
(and important) impact on morbidity.
The threat that a narrow focus on
selected interventions might displace
funding and attention from other impor-
tant interventions is accentuated by the
pressure on global health agencies to prove
their value. The global health landscape
has become crowded with different orga-
nisations, diseases, and interventions in-
creasingly competing for global health
funding and attention. What matters
increasingly is the achievement of a
narrow set of concrete, quantifiable, and
immediate results, leaving sustainability,
equity, long-term capacity development,
and comprehensive systems strengthening
to be of secondary importance.
The rhetorical power of measures of
‘‘lives saved’’ not only shapes the setting of
health priorities and budgets, but also
influences how global health actors inter-
act with partners in recipient countries.
Ideally, external funding should have an
indirect impact on health by catalysing
national health systems development and
supporting ministries of health and other
local agencies to perform more effectively.
But if external agencies are judged against
the delivery and impact of specific inter-
ventions, they may encourage vertical
programmes and stand-alone systems
(over which they can have greater control),
and neglect local institution building and
national systems strengthening.
These dangers are accentuated by the
reporting of results and health impact
without any accompanying analysis or
assessment of sustainability, efficiency, or
equity. Thus, while the last ten years
have seen a dramatic improvement in
ART, DOTS, and ITN coverage, it is
not apparent whether this has been
achieved optimally or efficiently (result-
ing in better health and lower cost), or if
lives were saved in ways that improved
equity and reduced levels of donor
dependency.
Discussion
This paper argues that the number of
‘‘lives saved’’ that are attributed to Global
Fund–supported programmes is not as
certain as has been suggested by The
Global Fund, and is likely to be an
overestimate. Furthermore, estimating the
‘‘lives saved’’ by Global Fund–supported
programmes is confusing and potentially
misleading, because such programmes
include a considerable but unstated
amount of financial support from other
sources. Finally, a number of potentially
negative policy effects are associated with
the selective impact estimation of down-
stream clinical interventions.
While this paper focuses on The Global
Fund, the issues raised here apply to other
global health partnerships and inter-
national donor agencies that are increas-
ingly under pressure to quantify the health
impact of their investments. The methods
Table 1. Potential causes for over- or underestimation of number of ‘‘lives saved’’ in The Global Fund’s model.
Intervention Cause of Underestimation Cause of Overestimation Net Effect
ART Optimistic assumptions about ART effectiveness, patient
retention and survival
Double counting of lives saved by ART and DOTS in
TB/HIV-co-infected patients
Overestimation
DOTS Noninclusion of the additional dynamic
effects of DOTs on reduced TB transmission
Pessimistic assumptions about TB fatality rates in untreated
patients
Choice of a ‘‘no-treatment’’ counterfactual
Likely overestimation, especially
given choice of counterfactual
ITNs Nonestimation of the effect of ITNs on
reducing mortality in children over the
age of five and in adults
Exclusion of countries outside sub-Saharan
Africa and Papua New Guinea
Optimistic assumptions of how grant-reported ITN
distributions translate into actual child usage of ITNs
Lives saved by ITNs will fall if ACT now also reduces malaria
deaths
Uncertain, perhaps neutral
doi:10.1371/journal.pmed.1001522.t001
Table 2. Global Fund’s share in service delivery results and programme financing, low- and middle-income countries.
Disease Service Delivery Measure Service Delivery Results
Global Fund Share in Programme
Financing, 2010
Global
Global Fund–Supported Programmes
(% of Global Results)
HIV/AIDS People alive on ART, end-2010 6.65 million [7] 3.0 million (45%) [7] 10% [46]
TB Patients treated under DOTS, for
smear-positive TB only, 2010 alone
2.6 million [7] 1.7 million (67%) [7] 11% [20]
Patients treated under DOTS, all
forms of TB, 2010 alone
5.6 million [9] 3.9 million (67%) [9]
Malaria ITNs distributed, in 2010 alone 145 million [9] 89 million (62%) [9] 45% [47]
doi:10.1371/journal.pmed.1001522.t002
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for estimating and attributing ‘‘lives saved,’’
and the consequences of doing so, should
be questioned and subjected to critical
debate.
In the case of The Global Fund, for a
start, greater clarity and explanation
about the assumptions and generalisa-
tions of the methods are required; this
should include publication of uncertainty
ranges and of disaggregated estimates of
‘‘lives saved’’ for each of the three
interventions and for each year. The
Global Fund should also conduct and
publish sensitivity analyses, particularly in
relation to treatment effectiveness, and
publish estimates of ‘‘lives saved’’ through
DOTS based on alternative counterfac-
tual scenarios.
If the health impact of ART, DOTS,
and ITNs is to be estimated in the form
of ‘‘lives saved,’’ we argue that this
should not be done as an exercise focused
on individual external agencies, but
rather on the collective contributions of
governments and development partners
within countries. This would confer a
number of benefits. First, the monitoring
of service delivery outputs and the
estimation of their health impact would
be linked to an assessment of the
performance of national health systems
(a more appropriate unit for assessment)
and the degree to which development
partners are working in harmonisation
with each other and in alignment with
ministries of health and their national
plans and priorities. This would help shift
more attention towards the strengthening
of integrated national plans and informa-
tion systems.
Second, holistic assessments of service
delivery results and health improvement at
the country level would allow for a
context-based analysis of performance,
including assessments of efficiency and
equity. This would be aided by cross-
country comparisons that would reveal
variations in effectiveness (and efficiency)
of ART, DOTS, and ITNs that arise from
differences in, amongst other things, access
to health care, quality of care and
treatment adherence, and population cov-
erage of nonclinical determinants of health
such as access to clean water and nutrition.
By describing this variation, policy atten-
tion can be directed not just at the delivery
of selected clinical interventions, but also
at the social, economic, and environmen-
tal conditions that influence the degree to
which those interventions are effective.
This stands in marked contrast to a
modelling approach that assumes stan-
dardised levels of effectiveness across
countries or regions.
Third, estimates of ‘‘lives saved’’ at the
country level might be more valid and
less uncertain because they would be
derived from more appropriate and
country-specific modelling assumptions,
and because it would motivate countries
to improve the quality of their data. In
addition, it could stimulate other actors
within countries, such as parliamentary
health committees, universities, and local
nongovernmental organizations, to devel-
op the capacity to scrutinise the perfor-
mance of the health system. While many
countries produce annual health reports,
health needs assessments, and national
health plans, which provide some descrip-
tion of progress in the health sector, they
are often incomplete or weak. Subnational
analyses are frequently absent or superfi-
cial; and the fragmented and piecemeal
nature of reporting systems, encouraged
by vertical and donor-driven DAH, still
undermines the development of coherent
planning, budgeting, management, and
information systems.
While an estimate of ‘‘lives saved’’ by
ART, DOTS, and ITNs at country level
would still be limited by its narrow focus
on three interventions, it would provide a
platform for monitoring and evaluating
other aspects of HIV, TB, and malaria
programmes and be more easily incorpo-
rated into a national system of data
collection and evaluation that takes into
account a wider package of health systems
inputs, processes, and outputs, enabling
policy makers and planners to consider the
importance of investments that do not
have a measurable or immediate mortality
impact.
If individual external agencies need to
estimate their specific contribution to
‘‘lives saved,’’ this could be done more
simply by apportioning a share of a
country’s estimated number of lives saved
on the basis of their proportional financial
contribution to THE or total HIV/AIDS,
TB, and malaria programme financing.
This would provide a more meaningful
assessment of the contribution of individ-
ual agencies, avoid double-counting in
reported estimates of ‘‘lives saved’’ by
external agencies, and incentivise external
agencies to promote coherent national
health planning and reporting.
Many of these recommendations (Box
3) are applicable to external agencies in
general. However, since 2012, The Global
Fund has been providing more active
support for detailed national evaluations
of programme performance and impact,
and more accurate measures of disease
incidence, prevalence, mortality, and mor-
bidity in 20 to 25 ‘‘high-impact’’ countries.
This provides it with an opportunity to
shift emphasis away from estimating ‘‘lives
saved’’ by individual interventions and
donor-supported programmes, towards
an assessment of health systems perfor-
mance and impact that incorporates all
major actors, programmes, and interven-
tions, and a fuller assessment of the
contribution of social, economic, and
other upstream determinants of health.
Box 3. Recommendations
The Global Fund should publish a clear explanation of the assumptions and
generalisations of its methods for calculating ‘‘lives saved’’ as well as uncertainty
ranges and disaggregated estimates of ‘‘lives saved’’ for each of the three
interventions and for each year.
The Global Fund should also conduct and publish sensitivity analyses, particularly
in relation to treatment effectiveness, and publish estimates of ‘‘lives saved’’
through DOTS based on alternative counterfactual scenarios.
Estimates of ‘‘lives saved’’ by ART, DOTS, and ITNs should not be focused on
individual external agencies, but rather on the collective contributions of
governments and all development partners within countries and using country-
specific modelling assumptions.
Holistic assessments of service delivery results and ‘‘lives saved’’ at the country
level should be accompanied by a context-based analysis of performance,
including assessments of efficiency and equity and by cross-country comparisons
that would reveal variations in the cost-effectiveness of ART, DOTS, and ITNs.
Should individual external agencies need to estimate their specific contribution to
‘‘lives saved,’’ this could be done more simply by apportioning a share of a
country’s overall estimate of ‘‘lives saved’’ on the basis of their proportional
financial contribution to THE or total HIV/AIDS, TB, and malaria programme
financing.
PLOS Medicine | www.plosmedicine.org 6 October 2013 | Volume 10 | Issue 10 | e1001522
Acknowledgments
The authors wish to thank Daniel Low-Beer
and Ryuichi Komatsu from The Global Fund
for their patient and helpful explanations,
comments, and corrections in reviewing several
drafts of the paper; Mary Mahy from UNAIDS
for explaining the latest developments related to
the Spectrum model; and Kalpana Sabapathy
and Roly Gosling for their views, comments,
and suggestions.
Author Contributions
Analyzed the data: DM NJ KK RF ELK.
Wrote the first draft of the manuscript: DM.
Contributed to the writing of the manuscript:
DM NJ KK RF ELK. ICMJE criteria for
authorship read and met: DM NJ KK RF ELK.
Agree with manuscript results and conclusions:
DM NJ KK RF ELK.
References
1. GAVI Alliance (2012) GAVI’s Impact. Available:
http://www.gavialliance.org/about/mission/
impact/. Accessed 10 May 2013.
2. World Bank (2012) World Bank: Health: Sector
Results Profile. Available: http://web.worldbank.
org/WBSITE/EXTERNAL/NEWS/0, content
MDK: 22883311,menuPK:64256345,pagePK:
34370,piPK:34424,theSitePK:4607,00.html.
Accessed 26 September 2012.
3. United States President’s Emergency Plan for
AIDS Relief (2012) AIDS 2012 Update: Latest
PEPFAR Results. Available: http://www.pepfar.
gov/funding/results/index.htm. Accessed 10
May 2013.
4. World Health Organization (2012) Global Tu-
berculosis Report 2012. Available: http://www.
who.int/tb/publications/global_report/en/. Ac-
cessed 7 May 2013.
5. Eisele TP, Larsen DA, Walker N, Cibulskis RE,
Yukich JO, et al. (2012) Estimates of child deaths
prevented from malaria prevention scale-up in
Africa 2001–2010. Malar J 11:93. doi: 10.1186/
1475-2875-11-93. Available: http://www.mala
riajournal.com/content/pdf/1475-2875-11-93.
pdf. Accessed 10 May 2013.
6. World Health Organization, UNAIDS, UNICEF
(2011) Global HIV/AIDS response. Epidemic
update and health sector progress towards
Universal Access. Progress report 2011. Avail-
able: http://www.unaids.org/en/media/unaids/
contentassets/documents/unaidspublication/
2011/20111130_UA_Report_en.pdf. Accessed
10 May 2013.
7. Global Fund to Fight AIDS, Tuberculosis and
Malaria, (2012) Strategic Investments for Impact.
Global Fund Results Report 2012. Available:
http://www.theglobalfund.org/en/library/
publications/progressreports/. Accessed 10 May
2013.
8. Komatsu R, Korenromp EL, Low-Beer D, Watt
C, Dye C, et al. (2010) Lives saved by Global
Fund-supported HIV/AIDS, tuberculosis and
malaria programs: Estimation approach and
results between 2003 and end-2007. BMC Infect
Dis 10:109. Available: http://www.biomed
central.com/1471-2334/10/109. Accessed 10
May 2013.
9. Global Fund (2012) Attachment 3. Background
Information on Goals and Targets for the Global
Fund Strategy 2012–2016. Available: http://
www.theglobalfund.org/en/about/strategy. Ac-
cessed 10 May 2013.
10. Global Fund (2011) The Global Fund Results
Report 2011: Making a Difference. Available:
http://www.theglobalfund.org/en/library/
publications/progressreports/. Accessed 14 Oc-
tober 2012.
11. Mahy M, Stover J, Stanecki K, Stoneburner R,
Tassie JM (2010) Estimating the impact of
antiretroviral therapy: regional and global esti-
mates of life-years gained among adults. Sex
Transm Infect 86 (Suppl 2): ii67–71.
12. Yiannoutsos CY, Johnson LF, Boulle A, Musick
BS, Gsponer T, et al. (2012) Estimated mortality
of adult HIV-infected patients starting treatment
with combination antiretroviral therapy. Sex
Transm Infect 88:Suppl 2 i33–i43. doi:10.1136/
sextrans-2012—050658. Available: http://www.
ncbi.nlm.nih.gov/pmc/articles/PMC3512431/.
Accessed 10 May 2013.
13. Rollins N, Mahy M, Becquet R, Kuhn L, Creek
T, et al. (2012) Estimates of peripartum and
postnatal mother-to-child transmission probabili-
ties of HIV for use in Spectrum and other
population-based models. Sex Transm Infect
88:Suppl 2 i44–i51. doi:10.1136/sextrans-2012-
050709. Available: http://www.emtct-iatt.org/
wp-content/uploads/2013/06/Estimates-of-
peripartum-and-postnatal-mother-to-child-
transmission-probabilities-of-HIV-for-use-in-
Spectrum-and-other-population-based-models.
pdf. Accessed 10 May 2013.
14. Mahy M (2012) Personal communication.
15. Tiemersma EW, van der Werf MJ, Borgdorff
MW, Williams BG, Nagelkerke NJ (2011) Natural
history of tuberculosis: duration and fatality of
untreated pulmonary tuberculosis in HIV nega-
tive patients: A systematic review. PLoS ONE 6:
e17601. Available: http://www.plosone.org/
article/info%3Adoi%2F10.1371%2Fjournal.
pone.0017601. Accessed 10 May 2013.
16. Glaziou P, Floyd K, Korenromp EL, Sismanidis
B, Bierrenbach A, et al. (2011) Lives saved by
tuberculosis control and prospects for achieving
the 2015 global target for reductions in tubercu-
losis mortality. Bull World Health Organ 89:
573–582. Available: http://www.who.int/
bulletin/volumes/89/8/11-087510.pdf. Accessed
10 May 2013.
17. Straetemans M, Bierrenbach AL, Nagelkerke N,
Glaziou P, van der Werf MJ (2010) The effect of
tuberculosis on mortality in HIV positive people:
a meta-analysis. PLoS ONE 5: e15241. Available:
http://www.plosone.org/article/info:doi/10.
1371/journal.pone.0015241?imageURI= info:doi
/10.1371/journal.pone.0015241.t001. Accessed
10 May 2013.
18. Mukadi JD, Maher D and Harries A (2001)
Tuberculosis case fatality rates in high HIV
prevalence populations in sub-Saharan Africa.
AIDS 15: 143–152. Available: http://journals.
lww.com/aidsonline/Fulltext/2001/01260/Site_
of_disease_and_opportunistic_infection.2.aspx.
Accessed 10 May 2013.
19. Korenromp EL, Glaziou P, Fitzpatrick C, Floyd
K, Hosseini M, et al. (2012) Implementing the
Global Plan to Stop TB, 2011–2015—Optimiz-
ing Allocations and the Global Fund’s Contribu-
tion: A Scenario Projections Study. PLoS ONE
7(6): e38816.Available: http://www.plosone.org/
article/info%3Adoi%2F10.1371%2Fjournal.
pone.0038816. Accessed 10 May 2013.
20. World Health Organization (2011) Global tuber-
culosis control 2011. Available: http://www.who.
int/tb/publications/global_report/2011/gtbr11_
full.pdf. Accessed 14 October 2012.
21. Guerra CA, Gikandi PW, Tatem AJ, Noor AM,
Smith DL, et al. (2008) The limits and intensity of
Plasmodium falciparum transmission: implica-
tions for malaria control and elimination world-
wide. PLoS Med 5: e38. Available: http://www.
plosmedicine.org/article/info:doi/10.1371/
journal.pmed.0050038. Accessed 10 May 2013.
22. Global Fund (2012) Methodology Web Annex.
Strategic Investment for Impact: Global Fund
Results Report 2012. Available: www.
theglobalfund.org/documents/publications/
progress_reports/Publication_2012Results_
Annext_en/. Accessed 10 May 2013.
23. Lengeler C (2004) Insecticide-treated bed nets
and curtains for preventing malaria. Cochrane
Database of Systemic Reviews 2: CD000363.
Available: http://www.thecochranelibrary.com/
userfiles/ccoch/file/CD000363.pdf. Accessed 10
May 2013.
24. Rosen S, Fox MP, Gill CJ (2007) Patient retention
in antiretroviral therapy programs in sub-saharan
Africa: a systematic review. PLoS Med 4: e298.
Available: http://www.plosmedicine.org/article/
info:doi/10.1371/journal.pmed.0040298. Ac-
cessed 10 May 2013.
25. Marston M, Becquet R, Zaba B, Moulton LH,
Gray G, et al. (2011) Net survival of perinatally
and postnatally HIV-infected children: a pooled
analysis of individual data from sub-Saharan
Africa. Int J Epidemiol 40(2): 385–396.
26. Tassie´ JM, Baijal P, Vitoria MA, Alisalad A,
Crowley SP, et al. (2010) Trends in retention on
antiretroviral therapy in national programs in
low-income and middle-income countries.
J Acquir Immune Defic Syndr 54: 437–441.
Available: http://journals.lww.com/jaids/
Fulltext/2010/08010/Trends_in_Retention_on_
Antiretroviral_Therapy_in.16.aspx. Accessed 10
May 2013.
27. Straetemans M, Glaziou P, Bierrenbach AL,
Sismanidis C, van der Werf MJ (2011) Assessing
Tuberculosis Case Fatality Ratio: A Meta-Anal-
ysis. PLoS ONE 6(6): e20755. Available: http://
www.plosone.org/article/info%3Adoi%2F10.
1371%2Fjournal.pone.0020755. Accessed 10
May 2013.
28. Korenromp EL, Arnold F, Williams BG, Nahlen
B, Snow RW (2004) Monitoring trends in under-
five mortality rates through national birth history
surveys. Int J Epid 33:1293–301.
29. Fox MP, Brennan A, Maskew M, MacPhail P,
Sanne I (2010). Using vital registration data to
update mortality among patients lost to follow-up
from ART programmes: evidence from the
Themba Lethu Clinic, South Africa. Trop Med
Int Health 15(4): 405–413.
30. Chi BH, Yiannoutsos CT, Westfall AO, Newman
JE, Zhou J, et al. (2011) Universal definition of
loss to follow-up in HIV treatment programs: a
statistical analysis of 111 facilities in Africa, Asia,
and Latin America. PLoS Med 8: e1001111.
Available: http://www.plosmedicine.org/article/
info%3Adoi%2F10.1371%2Fjournal.pmed.
1001111. Accessed 10 May 2013.
31. Brinkhof MW, Dabis F, Myer L, Bangsberg DR,
Boulle A, et al. (2008) Early loss of HIV-infected
patients on potent antiretroviral therapy pro-
grammes in lower-income countries. Bull World
Health Organ 86: 559–567. Available: http://
www.who.int/bulletin/volumes/86/7/07-
044248/en/index.html. Accessed 10 May 2013.
32. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell
C, et al. (2010) Treatment interruption in a
primary care antiretroviral therapy program in
South Africa: cohort analysis of trends and risk
factors. J Acquir Immune Defic Syndr 55: e17–
23. Available: http://journals.lww.com/jaids/
Fulltext/2010/11010/Treatment_Interruption_
in_a_Primary_Care.20.aspx. Accessed 10 May
2013.
33. Nglazi MD, Lawn SD, Kaplan R, Kranzer K,
Orrell C, et al. (2011) Changes in programmatic
outcomes during 7 years of scale-up at a
community-based antiretroviral treatment service
in South Africa. J Acquir Immune Defic Syndr
56: e1–8. Available: http://journals.lww.com/
PLOS Medicine | www.plosmedicine.org 7 October 2013 | Volume 10 | Issue 10 | e1001522
ja ids/Full text/2011/01010/Changes_in_
Programmatic_Outcomes_During_7_Years_of.
10.aspx. Accessed 10 May 2013.
34. Boulle A, Van Cutsem G, Hilderbrand K, Cragg
C, Abrahams M, Mathee S, et al. (2010) Seven-
year experience of a primary care antiretroviral
treatment programme in Khayelitsha, South
Africa. AIDS 24: 563–72. Available: http://msf.
openrepository.com/msf/bitstream/10144/
95573/1/Khaylelitsha%20AIDS%202010.pdf.
Accessed 10 May 2013.
35. Mwagomba B, Zachariah R, Massaquoi M,
Misindi D, Manzi M, et al. (2010) Mortality
reduction associated with HIV/AIDS care and
antiretroviral treatment in rural Malawi: evidence
from registers, coffin sales and funerals. PLoS
ONE 5(5): e10452. Available: http://www.
plosone.org/article/info:doi/10.1371/journal.
pone.0010452. Accessed 10 May 2013.
36. Aungkulanon S, McCarron M, Lertiendumrong
J, Olsen SJ, Bundhamcharoen K (2012) Infectious
disease mortality rates, Thailand, 1958–2009.
Emerg Infect Dis 18(11). Available: http://dx.
doi.org/10.3201/eid1811.120637.
37. Herbst AJ, Cooke GS, Ba¨rnighausen T, Kany-
Kany A, Tanser F, et al. (2009) Adult mortality
and antiretroviral treatment roll-out in rural
KwaZulu-Natal, South Africa. Bull World Health
Organ. 87(10): 754–762. Available: http://www.
who.int/bulletin/volumes/87/10/08-058982/
en/. Accessed 10 May 2013.
38. Stoneburner R, Korenromp EL, et al. (2011)
Health impact of HIV and TB interventions in
Botswana: initial findings and recommendations
to improve empirical evidence and strategic
information for program evaluation. Report of
UNAIDS, WHO, and Global Fund joint mission,
Gaborone, Botswana, 16–24th September 2010.
March 2011. Geneva/Gaborone, UNAIDS,
WHO HIV/AIDS dept., the Global Fund to
fight AIDS, Tuberculosis and Malaria.
39. Jahn A, Floyd S, Crampin AC, Mwaungulu F,
Mvula H, et al. (2008) Population-level effect of
HIV on adult mortality and early evidence of
reversal after introduction of antiretroviral ther-
apy in Malawi. Lancet 371(9624): 1603–1611.
Available: http://www.thelancet.com/journals/
lancet/article/PIIS0140-6736%2808%2960693-
5/fulltext. Accessed 10 May 2013.
40. Korenromp EL (2012) Lives saved from malaria
prevention in Africa – evidence to sustain cost-
effective gains. Malar J 11: 94. Available: http://
www.malariajournal.com/content/11/1/94. Ac-
cessed 10 May 2013
41. Lim SS, Fullman N, Stokes A, Ravishankar N,
Masiye F, et al. (2011) Net Benefits: A Multi-
country Analysis of Observational Data Examin-
ing Associations between Insecticide-Treated
Mosquito Nets and Health Outcomes. PLoS
Med 8(9): e1001091. Available: http://www.
plosmedicine.org/article/info%3Adoi%2F10.
1371%2Fjournal.pmed.1001091. Accessed 10
May 2013.
42. Aregawi M, Ali AS, Al-mafazy A, Molteni F,
Katikiti S, et al. (2011) Reductions in malaria and
anemia case and death burden to hospitals
following scale-up of malaria control in Zanzibar,
1999–2008. Malar J 10: 46. Available: http://
www.malariajournal.com/content/pdf/1475-
2875-10-46.pdf. Accessed 10 May 2013.
43. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG,
Foreman KJ, et al. (2012) Global malaria
mortality between 1980 and 2010: a systematic
analysis. Lancet 379(9814): 413–431. Available:
http://www.thelancet.com/journals/lancet/
article/PIIS0140-6736%2812%2960034-8/
fulltext. Accessed 10 May 2013.
44. Lynch M, Korenromp EL, Eisele T, Newby H,
Steketee R, Kachur P, et al. (2012) New global
estimates of malaria deaths. Lancet 380(9841):
559. Available: http://www.thelancet.com/
journals/lancet/article/PIIS0140-6736%2812%
2961320-8/fulltext. Accessed 10 May 2013.
45. Global Fund (2011) Global Fund Results Fact
Sheet, end-2011. Available: http://www.
theglobalfund.org/documents/diseases/hivaids/
HIV_ARVEnd2011_FactSheet_en/. Accessed 10
May 2013.
46. Kates J, Boortz K, Lief E, Avila C, Gobet B
(2010) Financing the Response to AIDS in Low-
and Middle-Income Countries: International
Assistance from the G8, European Commission
and Other Donor Governments in 2009. Kaiser
Family Foundation, The Stimson Center, UN-
AIDS. Available: http://kaiserfamilyfoundation.
files.wordpress.com/2013/01/7347-06.pdf. Ac-
cessed 14 January 2012.
47. World Health Organization (2011) World Malar-
ia Report 2011. Available: www.who.int/
malaria/world_malaria_report_2011/en. Ac-
cessed 10 May 2013.
48. McCoy D, Kinyua K (2012) Allocating Scarce
Resources Strategically: An Evaluation and
Discussion of the Global Fund’s Pattern of
Disbursement. PLoS ONE 7(5): e34749. Avail-
ab le : h t tp ://www.p losone .org/ar t i c l e/
info%3Adoi%2F10.1371%2Fjournal.pone.
0034749. Accessed 10 May 2013.
49. Global Fund (2011) Global Fund Results Fact
Sheet, mid-2011. Available: http://www.
theglobalfund.org/documents/diseases/hivaids/
HIV_ARVMid2011_FactSheet_en/. Accessed 10
May 2013.
PLOS Medicine | www.plosmedicine.org 8 October 2013 | Volume 10 | Issue 10 | e1001522
